Please ensure Javascript is enabled for purposes of website accessibility

The Run Isn't Over for This Booming Biotech

By Dan Carroll - Sep 7, 2013 at 11:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NPS Pharmaceuticals has soared in 2013, but is there still time for you to reap this stock's rewards?

Few stocks in any sector have had the kind of thriving 2013 that NPS Pharmaceuticals (NASDAQ: NPSP) has enjoyed. This biotech stock's up more than 200% year-to-date after receiving approval from the Food and Drug Administration late last year for Gattex, its orphan drug treatment for the rare condition small bowel syndrome, or SBS. Gattex has gotten off to a good start in the first six months of the year, opening up a small but solid patient base as NPS looks to get this rising star going.

It's just the start for Gattex: NPS is hoping the drug can catch on abroad as well, and even conservative peak sales estimates show that this drug has plenty of room to run. But considering this stock's astronomical rise in 2013, have investors who overlooked this stock through most of 2013 missed their chance at big gains?

Fortunately, NPS Pharmaceuticals has plenty of momentum going forward-momentum that could carry shares even higher in the future. In the video below, Fool contributor Dan Carroll tells you what to look for out of NPS in coming quarters -- and how this stock's on pace to keep rising higher over the long term.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$10,714.00 (-1.40%) $-152.00
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$247.29 (0.42%) $1.04
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$302.50 (0.39%) $1.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.